Halozyme Therapeutics Executive Compensation
Halozyme Therapeutics is a publicly traded company in the Healthcare sector.
Named Executive Officers — FY2025
Compensation Analysis
Computed directly from SEC-sourced figures tracked on this page — not a general description.
Halozyme Therapeutics discloses FY2025 compensation for 5 named executive officers, totaling $37.5M. Helen I. Torley, the Executive Officer, accounts for 62% of that combined total.
Helen I. Torley's total compensation rose 82% year-over-year, from $12.7M in FY2024 to $23.2M in FY2025.
Cash compensation (salary plus bonus) made up 8% of Halozyme Therapeutics's FY2025 tracked executive pay, with stock awards accounting for 86%. That's notably more stock-weighted than the typical Healthcare company in this dataset, where stock awards average 0% of tracked pay.
Among 78 other Healthcare companies in this dataset, Halozyme Therapeutics's combined tracked executive pay of $37.5M ranks in the 86th percentile (industry median: $12.5M). Its highest-paid executive, Helen I. Torley, ranks in the 94th percentile for top-executive pay in the sector (industry median: $6.0M).